Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.73 |
| ▸ | TPH1 | P17752 | 3/20 | 0.60 |
| ▸ | SLC7A5 | Q01650 | 5/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | FYN | P06241 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31242504 | 1.00 | LDHA (0.73) | LDHATPH1SLC7A5PTGS1ALOX15 | |
| SCHEMBL30013904 | 1.00 | LDHA (0.73) | LDHATPH1SLC7A5PTGS1ALOX15 | |
| SCHEMBL159001 | 1.00 | LDHA (0.73) | LDHATPH1SLC7A5PTGS1ALOX15 | |
| SCHEMBL159000 | 1.00 | LDHA (0.73) | LDHATPH1SLC7A5PTGS1ALOX15 | |
| SCHEMBL29637606 | 1.00 | LDHA (0.73) | LDHATPH1SLC7A5PTGS1ALOX15 | |
| Hydrochloric Acid SCHEMBL3207583 | 0.98 | LDHA (0.71) | LDHATPH1SLC7A5PTGS1ALOX15 | |
| Hydrochloric Acid SCHEMBL10464213 | 0.98 | LDHA (0.71) | LDHATPH1SLC7A5PTGS1ALOX15 | |
| SCHEMBL10426009 | 0.91 | LDHA (0.61) | LDHATPH1SLC7A5PTGS1ALOX15 | |
| SCHEMBL10426010 | 0.91 | LDHA (0.61) | LDHATPH1SLC7A5PTGS1ALOX15 | |
| SCHEMBL10705215 | 0.91 | LDHA (0.61) | LDHATPH1SLC7A5PTGS1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121518450-A | Amino-acylase mutant and application thereof in preparation of D-3, 4-dimethoxy phenylalanine | 山东新华制药股份有限公司 | 2026-02-13 | — | — | CN | disclosed |
| CN-121518450-A | Amino-acylase mutant and application thereof in preparation of D-3, 4-dimethoxy phenylalanine | 山东新华制药股份有限公司 | 2026-02-13 | — | — | CN | disclosed |
| US-12173018-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20210198288-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2021-07-01 | — | — | US | disclosed |
| EP-3802551-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| CN-112469725-A | Penicillin binding protein inhibitors | 维纳拓尔斯制药公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-110072883-A | The relevant peptide of therapeutic MOTS-C | 科巴公司 | 2019-07-30 | — | — | CN | disclosed |
| US-9540620-B2 | Methods and compositions for modulating G-alpha-Q signaling | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150218538-A1 | Methods and Compositions for Modulating G-Alpha-Q Signaling | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-06 | — | — | US | disclosed |
| EP-0850316-A4 | CRYPTOPHYCINS FROM ABERRANT BIOSYNTHESIS | UNIV HAWAII (US) | 2000-08-23 | — | — | EP | disclosed |
| EP-0850316-A1 | CRYPTOPHYCINS FROM ABERRANT BIOSYNTHESIS | UNIVERSITY OF HAWAII (US) | 1998-07-01 | — | — | EP | disclosed |
| WO-1997008334-A1 | CRYPTOPHYCINS FROM ABERRANT BIOSYNTHESIS | UNIVERSITY OF HAWAII (US) | 1997-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198288-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | LDHA 2079/4885TPH1 4328/4885SLC7A5 1717/4885 |
| US-12173018-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | LDHA 2079/4885TPH1 4328/4885SLC7A5 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.